Investor Alert

London Markets Open in:

Market Pulse Archives

April 30, 2021, 8:45 a.m. EDT · CORRECTED

AbbVie's stock is up 2.0% as Humira sales top $4.8 billion in sales in the first quarter

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AbbVie Inc. (ABBV)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

An earlier version of this report incorrectly stated sales figures for Humira.

Shares of AbbVie Inc. /zigman2/quotes/202428675/composite ABBV +0.33% gained 2.0% in premarket trading on Friday after it beat earnings expectations and saw a noticeable jump in pharmaceutical revenue for the first quarter of 2021. The diagnostics company had earnings of $3.5 billion, or $1.99 earnings per share, in the first quarter of 2021, compared with $3.0 billion, or $2.02 earnings per share, in the same quarter a year ago. AbbVie's adjusted earnings per share for the quarter were $2.95, against a FactSet consensus of $2.81. The company generated $13.0 billion in revenue for the quarter in 2021, up from $8.6 billion in the same quarter in 2020. The FactSet consensus was $12.7 billion. Rheumatoid arthritis drug Humira remains AbbVie's top-selling drug with $4.8 billion in sales, up from $4.7 billion in the same quarter a year ago. Botox, the cosmetic filler, had sales of $477 million. AbbVie closed its acquisition of Allergan, which marketed Botox, in May of last year. The company raised its guidance for the year, with adjusted EPS projected to be $12.37 to $12.57 for 2021, from $12.32 to $12.52. AbbVie's stock is up 3.5% for the year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.32% has gained 12.1%.

$ 116.89
+0.38 +0.33%
Volume: 4.37M
Nov. 29, 2021 4:02p
P/E Ratio
Dividend Yield
Market Cap
$205.98 billion
Rev. per Employee
+60.65 +1.32%
Volume: 2.50B
Nov. 29, 2021 4:57p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.